PA
TVGN icon

Parallel Advisors’s Tevogen Bio Holdings TVGN Stock Holding History

Parallel Advisors’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$13 – 3971
2025
Q4 		$13 Hold
1
– – ﹤0.01% 3604
2025
Q3 		$31 Hold
1
– – ﹤0.01% 3521
2025
Q2 		$50 Buy
+1
New +$57 ﹤0.01% 3493

Other funds holding TVGN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Parallel Advisors's TVGN Position: Q1 2026 in Review

Parallel Advisors sold out of Tevogen Bio Holdings (TVGN) in Q1 2026, closing a stake of 1 share — an estimated $13 sold.

Parallel Advisors first reported a position in TVGN in Q2 2025 and held it in 3 quarters. The position peaked at $50 in Q2 2025. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

  • Parallel Advisors reported no remaining Tevogen Bio Holdings position as of Q1 2026 after selling out during the quarter.
  • Parallel Advisors sold 1 Tevogen Bio Holdings share in Q1 2026, an estimated $13.
  • Parallel Advisors first reported a position in Tevogen Bio Holdings in Q2 2025 and held it in 3 quarters.
  • Parallel Advisors's Tevogen Bio Holdings position peaked at $50 in Q2 2025.
  • 30 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.